Nasivin (Oxymetazoline Hydrochloride)

Oxymetazoline Hydrochloride is an alpha‑adrenergic agonist used to relieve nasal congestion in several common conditions.

• Common cold: reduces swelling of nasal mucosa to improve airflow.
• Sinusitis: alleviates blockage of sinus passages, helping drainage.
• Allergic rhinitis: diminishes nasal obstruction caused by allergic inflammation.

• Oxymetazoline Hydrochloride acts as a selective alpha‑1 adrenergic receptor agonist on the blood vessels of the nasal mucosa. Activation causes vasoconstriction, which decreases blood flow, reduces mucosal edema, and opens the nasal airway, providing rapid decongestion without systemic vasoconstrictive effects at recommended doses.

Oxymetazoline Hydrochloride may cause local and systemic adverse reactions, most of which are mild and transient.

Common Side Effects

• Nasal irritation or burning sensation.
• Dryness of nasal passages.
• Sneezing.
• Headache.
• Rebound congestion with prolonged use.
• Transient taste disturbance.

Serious or Rare Side Effects

• Elevated blood pressure or hypertension.
• Rapid heart rate (tachycardia) or arrhythmia.
• Severe nasal ulceration or epistaxis.
• Allergic reactions such as rash, itching, or swelling.
• Anaphylaxis (rare but life‑threatening).
• Central nervous system effects like dizziness or anxiety.

Before using Nasivin, consider the following safety measures.

• Duration of use: limit to no more than three consecutive days to avoid rebound congestion.
• Age restrictions: avoid use in children under six years unless directed by a healthcare professional.
• Cardiovascular disease: use with caution in patients with hypertension or heart disease.
• Pregnancy and lactation: consult a physician; safety data are limited.
• Concurrent nasal medications: do not combine with other topical decongestants.
• Store at room temperature: keep in the original container, protect from moisture and direct heat.

Oxymetazoline may interact with other drugs, altering its safety profile.

Major Interactions (Avoid)

• Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis.
• Other topical nasal decongestants: additive vasoconstriction may increase blood pressure.

Moderate Interactions (Monitor Closely)

• Systemic sympathomimetics (e.g., pseudoephedrine): may enhance cardiovascular effects.
• Antihypertensive agents: possible reduction in blood‑pressure‑lowering efficacy.
• Tricyclic antidepressants: may increase risk of tachycardia.
• Beta‑blockers: monitor for altered heart rate response.
• Herbal stimulants (e.g., ephedra): potential additive sympathomimetic activity.